New Issue: Orbital Catastrophe Ahead? Read Now

Nice Germs Finish Last: "Good Samaritan" Bacteria Provide New Clues in Antibiotic Resistance

Resistant bacteria help their kin survive antibiotics, but at a cost

Join Our Community of Science Lovers!

The world is full of Good Samaritans; you’ll find many of them in your own body. James J. Collins, a biologist at Boston University, has found that small numbers of drug-resistant bacteria help their vulnerable counterparts survive antibiotic onslaughts, even at a cost to themselves.

Collins and his colleagues exposed one culture of Escherichia coli—some strains of which colonize the human and animal gut; others of which are notorious for causing disease outbreaks—to increasing amounts of an antibiotic over time. When they periodically analyzed the levels of drug resistance in the colony, they saw something un­expected: although the entire popu­lation was thriving in the presence of the drug, only a few individual bacteria were actually resistant. “We were really surprised to see that the levels of resistance of the individual isolates were considerably lower than the population as a whole,” explains Collins, who published his results recently in Nature. (Scientific American is part of Nature Publishing Group.) Further analysis revealed that the resistant mutants were secreting a molecule called indole that thwarts their own growth but helps the rest of the population survive by activating drug-export pumps on the bacterial cell membranes.

The findings could spur scientists to develop better antibiotics. If indole allows pathogenic bacteria to withstand antibiotics, it may be possible to thwart drug resistance by blocking indole signaling with small molecules, Collins says. Alternatively, “the findings suggest the possibility that scientists could one day use indole or an indole-based therapeutic, if proven safe, to help beneficial bacteria outcompete pathogenic bacteria in the urinary tract or intestinal system,” says Mark Anderson, chief scientific officer of Emeryville, Calif.–based Nova­Bay Pharmaceuticals, which develops drugs for antibiotic-resistant infections.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The results may also change the way doctors track infections in their patients. If a bacterial population can become antibiotic-resistant even when only a small number of individuals have the appropriate genetic mutations, doctors who collect and analyze small bacterial specimens from patients may underestimate just how resistant the infection is as a whole, Collins notes. “These unicellular organisms can function as a multicellular organism of sorts,” he says. Thus, isolated samples may not be representative of the big picture.

Melinda Wenner Moyer, a contributing editor at Scientific American, is author of Hello, Cruel World! Science-Based Strategies for Raising Terrific Kids in Terrifying Times (G. P. Putnam’s Sons, 2025).

More by Melinda Wenner Moyer
Scientific American Magazine Vol 303 Issue 5This article was published with the title “Nice Germs Finish Last: 'Good Samaritan' Bacteria Provide New Clues in Antibiotic Resistance” in Scientific American Magazine Vol. 303 No. 5 ()
doi:10.1038/scientificamerican112010-7hDqwX99Ky0at0vybDhlRa

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe